Literature DB >> 16829348

Statins for hyperlipidemia in patients with chronic liver disease: are they safe?

Raj Vuppalanchi, Naga Chalasani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16829348     DOI： 10.1016/j.cgh.2006.04.020

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  7 in total

Review 1.  Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?

Authors:  Munechika Enjoji; Makoto Nakamuta
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

Review 2.  Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.

Authors:  Rossana M Calderon; Luigi X Cubeddu; Ronald B Goldberg; Eugene R Schiff
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

Review 3.  Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease.

Authors:  Kathleen E Corey; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-17       Impact factor: 11.382

Review 4.  Lipid-lowering agents that cause drug-induced hepatotoxicity.

Authors:  Sidharth S Bhardwaj; Naga Chalasani
Journal:  Clin Liver Dis       Date:  2007-08       Impact factor: 6.126

5.  Statins in primary biliary cirrhosis: are they safe?

Authors:  Murad Abu Rajab; Marshall M Kaplan
Journal:  Dig Dis Sci       Date:  2009-10-01       Impact factor: 3.199

6.  Prescribing medications in patients with decompensated liver cirrhosis.

Authors:  Deepak N Amarapurkar
Journal:  Int J Hepatol       Date:  2011-08-22

Review 7.  NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.

Authors:  Stephen Caldwell
Journal:  Clin Mol Hepatol       Date:  2017-05-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.